Page last updated: 2024-08-23
paclitaxel and ym 529
paclitaxel has been researched along with ym 529 in 1 studies
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Kimura, S; Maekawa, T; Nogawa, M; Sato, K; Segawa, H; Yokota, A; Yuasa, T | 1 |
Other Studies
1 other study(ies) available for paclitaxel and ym 529
| Article | Year |
|---|---|
A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Carcinoma, Renal Cell; Cell Proliferation; Cisplatin; Diphosphonates; Drug Synergism; Drug Therapy, Combination; Female; Humans; Imidazoles; In Vitro Techniques; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Paclitaxel; Protein Prenylation; rap1 GTP-Binding Proteins; ras Proteins; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2006 |